fda warning about semaglutide semaglutide - I accidentally injected too muchsemaglutide FDA has warned companies that have illegally sold unapproved drugs containing semaglutide FDA Warning About Semaglutide: Navigating Risks and Ensuring Safety

Semaglutidecyanocobalamin side effects The U.S.Possible Side Effects of Ozempic ® (semaglutide) Injection Food and Drug Administration (FDA) has issued a significant warning about semaglutide, a potent medication primarily known for its role in managing type 2 diabetes and, more recently, for weight loss7天前—FDA removed semaglutide from the drug shortage list in February 2025. When the U.S. Food and Drug Administration declared that Ozempic® and .... Recent alerts from the FDA highlight serious concerns regarding unapproved versions of the drug, compounded semaglutide, and potential dosing errors.Update on FDA's ongoing evaluation of reports of suicidal ... This warning comes as a crucial reminder for both healthcare providers and patients to exercise vigilance and prioritize safety when using these powerful medications.

Semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs work by mimicking a natural hormone that helps regulate blood sugar levels2026年1月13日—FDA Requests Removal of Suicidal Behavior and Ideation Warningfrom Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications.. However, their efficacy and the growing demand have unfortunately led to the proliferation of unapproved and potentially unsafe alternatives. The FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled "for research." This practice poses a significant threat to public health, as the purity, potency, and safety of these illicit products are not guaranteed.

A primary concern raised by the FDA relates to compounded semaglutide. While compounding can be a valuable service for patients with specific needs, the FDA warns of dosing errors with compounded injectable semaglutideFDA Issues Class II Recall for Wegovy (Semaglutide) Prefilled Pens Due .... Reports have surfaced of individuals accidentally overdosing, administering significantly higher doses than prescribed – sometimes as much as 20 times more than the recommended amount. These dosing errors can lead to severe adverse events. The FDA has received reports of people overdosing on compounded semaglutide, resulting in adverse events and significant health risks.

The reported side effects associated with semaglutide overdose and improperly compounded versions are concerning. These include severe gastrointestinal effects, such as intense nausea, vomiting, and abdominal pain. Other reported issues include fainting and headaches7天前—FDA removed semaglutide from the drug shortage list in February 2025. When the U.S. Food and Drug Administration declared that Ozempic® and .... Furthermore, the FDA has noted that some compounded semaglutide may originate from foreign suppliers with varying manufacturing standards, increasing the risk of contamination or incorrect formulation. Therefore, taking compounded “semaglutide” can pose significant safety risks.

Beyond the immediate risks of overdose and adverse gastrointestinal reactions, the FDA has also addressed other potential safety concerns. The semaglutide label has a boxed warning about the risk of thyroid C-cell tumors, advising against its use in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Additionally, studies have indicated that semaglutide can increase the risk of developing Deep Vein Thrombosis (DVT) by 266%. While the FDA is continuously evaluating reports and issuing guidance, the potential for serious, long-term health complications cannot be overlooked.

The regulatory landscape surrounding semaglutide has seen active engagement from the FDA. The agency has issued warning letters to companies involved in selling unapproved and misbranded versions of semaglutide and tirzepatide2天前—As we reported here, on September 16, 2025,FDApublished over 55warningletters to online sellers of compounded versions of GLP-1, .... There have also been instances of product recalls, such as a Class II recall for Wegovy (semaglutide) prefilled pens due to potential issues. The FDA has also warned consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain, emphasizing the importance of obtaining medications from legitimate sources.

It is crucial to note that while the FDA monitors for adverse events, including reports of suicidal thoughts or actions potentially linked to GLP-1 receptor agonists, the agency has also been evaluating and, in some cases, has Requests Removal of Suicidal Behavior and Ideation Warning from these medications, indicating a nuanced and evolving understanding of these risks.

The FDA has actively worked to address the drug shortage of semaglutide injection products. In February 2025, the FDA removed semaglutide from the drug shortage list, signaling an improvement in availability for approved formulations. This is a critical development for patients who rely on these medications for managing their health conditions.

In summary, the FDA warning about semaglutide underscores the critical importance of adhering to prescribed dosages, obtaining medications from reputable sources, and being aware of the potential risks associated with unapproved and compounded versionsThe FDA has issued a new warning about a popular .... Patients and healthcare providers must remain informed, communicate openly about any concerns, and prioritize safe and effective use of these powerful medications.